The TIDES-ACS TRIAL
Key Findings at 60 months follow up
The TIDES-ACS randomized controlled trial is the first trial comparing the new Optimax Titan bioactive stent (Co-Cr platform) against the Best-in-Class 3rd generation Everolimus-Eluting Stent Synergy, from Boston Scientific in ACS (STEMI/NSTEMI) patients at 18 months and 60 months follow ups.
Study results confirmed a slight difference (p=NS) in the rate of MACE favoring the TiNO coated stent (11.2%) versus the biodegradable polymer EES (12%) and maintained significant difference (6.8% vs. 10%, p=0.03) in favor of the TiNO coated stent in the co-primary composite outcome of Safety.
Significant reductions in Cardiac death (0.9% vs. 3%, p=0.005), MI (4.6% vs. 7%, p=0.049) and stent thrombosis (1.2% vs. 2.8%, p=0.03) in favor of the TiNO coated stent were also observed at 5 years. In addition, at 5 years as at 18 months alike, there was no significant difference in TLR (Target Lesion Revascularisation) between both groups confirming the long-term efficacy of the TiNO bioactive coating.
“… the results of TiDES-ACS study are very consistent with previous Randomized Controlled Trials (RCTs) like TiTAX-AMI and BASE-ACS with similar trends in regards to Cardiac death and AMI…”
Dr Bouisset, Aalst Belgium
0.9%
Cardiac death at 60 months vs. 3.0% for Synergy™
(p = 0.005)
4.6%
MI at 60 months vs. 7.0% for Synergy™ (p = 0.049)
1.2%
thrombosis at 60 months vs. 2.8% for Synergy™ (p = 0.03)
If you want a copy of the study please contact your Hexacath representative.